What did REDEFINE 1 report against each of its component arms?

The receptor pharmacology I can follow; the in vivo translation is where I lose the thread.

I would like help reading this properly rather than being told what conclusion to reach.

I have the full report including the method section, so I can quote specifics if that helps.

What would I need in addition before this supported a decision?

This is a good example of expectation management: a strong result read as a disappointment because the pre-trial expectation had drifted.

Cagrilintide is an acylated long-acting amylin analogue designed for weekly administration; semaglutide is the GLP-1 agonist component. The receptors are unrelated, which is the basis for additivity.

REDEFINE-1 reported mean weight reduction around twenty-two to twenty-three per cent at 68 weeks in adults with obesity and without diabetes, against roughly sixteen per cent for semaglutide alone and about eleven for cagrilintide alone in the same trial.

The caveat is that a fixed combination has a tolerability profile of its own that cannot be inferred by adding the components.

Fixed combination means fixed ratio. That is a real constraint.

The honest answer is that the combination works, that the margin over semaglutide alone is real, and that it was smaller than the phase 2 signal suggested.

The pre-trial expectation in some quarters had drifted towards twenty-five per cent, so a result above every comparator was received as a shortfall. That is a lesson about expectations rather than about the compound.

Both components act at the area postrema, so the gastrointestinal tolerability profile is not simply the sum of the two and the titration schedule reflects that.

The amylin receptor architecture — calcitonin receptor plus RAMP — is established pharmacology and explains why selectivity was hard.

Both components hit the area postrema, which is why titration is careful.

edited 30 Jul 2024 by Dr_Colm_Fitzhenry — added the method parameters

Answer first: a fixed combination of cagrilintide, a long-acting amylin analogue, with semaglutide — two mechanisms, two receptors, one weekly injection.

For research-grade material, a combination is two identity problems and two content problems rather than one, and there is no reason to expect a supplier to have solved either.

Two mechanisms, two receptors, one injection. That is the design.

edited 30 Jul 2024 by h_pergande — reworded for clarity after a comment

On the detail: tolerability of the combination is the practical question, since both components act at the same brainstem region.

The glycaemic component in the diabetes population behaves differently from the weight component, and the two trials in the programme should be read separately.

Research-use combination material is not approved for human use and doubles the characterisation problem.

Read REDEFINE against the monotherapy arms, not against placebo.

edited 14 Aug 2024 by sian_llewellyn — added the citation requested in comments